About Advanced Cyclotron Systems
Advanced Cyclotron Systems (ACSI) manufactures cyclotron equipment that includes PET and SPECT radioisotope production cyclotrons. It manufactures, supplies, and services cyclotrons predominantly used for the production of medical isotopes by hospitals for nuclear medicine. The company was founded in 2003 and is based in Richmond, Canada.
Missing: Advanced Cyclotron Systems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Advanced Cyclotron Systems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Advanced Cyclotron Systems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Advanced Cyclotron Systems is included in 1 Expert Collection, including Pet Technologies.
This collection includes startups that make pet food, treats, and accessories, pet-focused retailers, and pet services like dog walking marketplaces and vet clinics.
Latest Advanced Cyclotron Systems News
Jul 1, 2022
and Global Analysis By Type [Ring Cyclotron, and Azimuthally Varying Field ], Capacity, and End User" - https://www.reportlinker.com/p06289920/?utm_source=GNW However, the high cost of procedures and lack of expertise are restricting the growth of the medical cyclotron market. Cyclotron therapy is commonly used to treat several types of cancer.The prevalence of cancer is increasing every year. Proton beam therapy is used to treat tumors that do not spread in the body and, thus, do not require brain surgery. The procedure is suitable for children as it prevents harm to healthy, growing tissues. Furthermore, it is used to treat eye cancers such as orbital rhabdomyosarcoma and retinoblastoma.Radiotherapy is a scientifically sophisticated way to diagnose and treat cancer. According to the National Cancer Institute, the US government spent US$ 208.9 billion on cancer treatment in 2020 The increase in the development of artificial radionuclides, the surge in the number of therapies, and the rise in the prevalence of cancer are driving the growth of medical cyclotron market. Based on type, the medical cyclotron market is segmented into ring cyclotron and azimuthally varying fields (AVF).The ring cyclotron segment to hold the largest share of the market in 2022. The same segment is estimated to register the highest CAGR during 2022–2028.Cyclotron therapy is commonly used to treat several types of cancer. The prevalence of cancer is increasing every year.Proton beam therapy is used to treat tumors that do not spread in the body and, thus, do not require brain surgery. The procedure is suitable for children as it prevents harm to healthy, growing tissues. Ring cyclotron is used for proton therapy; it utilizes high-energy beams of accelerated protons to treat cancer. A ring cyclotron is used for proton therapy and is designed with a CC-18/9 cyclotron used as an injector. As the ring cyclotron delivers high-intensity radiation, it targets only cancer cells and does not hamper non-cancerous cells. It takes nearly 10 to 20 microseconds for the acceleration of proton therapy. Thus, it helps control the beam by turning and switching off for low energy and the end of the therapy session. Proton therapy targets only cancerous cells and maintains the biological property of other cells. Therefore, it is expected to increase the demand for ring cyclotrons in medical applications. Also, the growing incidence of cancer worldwide is likely to influence the market’s growth during the forecast period. The comparative company analysis evaluates and categorizes the medical cyclotron market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion) and geographic presence that aids businesses in better decision making and understanding the competitive landscape. The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the global medical cyclotron market, including General Electric Company; Best ABT Molecular Imaging, Inc.; IBA; Sumitomo Heavy Industries, Ltd.; Siemens AG; Advanced Cyclotron Systems; ISOSOLUTION; ALCEN; IONETIX Corporation; and Best Cyclotron System, Inc. The key company initiating a distinct growth strategy will have a high potential to grow the global medical cyclotron market.The above data signifies the recent development activities and the presence of robust companies in their respective field. Competitive growth strategies in terms of markets help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.It represents continuous merger and acquisition strategy, geographical expansion, research and development, and optimal or advantageous suitability for adopting new product launch strategies for further business expansion and growth during the forecast period. This graph provides the depth and breadth of the vendors and one of the key understandings while developing the global medical cyclotron market penetration strategies. • Best ABT Molecular Imaging introduced their newest Best Sub-Compact Model 200 Self-Shielded Cyclotron for producing a range of radioisotopes for Medical and Research Applications at the push of a button. This cyclotron can be installed with one or more chemistry modules next to a PETCT/PET-MRI. • Sumitomo Heavy Industries, Ltd. conducted proton beam acceleration tests on its in-house developed superconducting cyclotron for the next-generation proton therapy system under development. They confirmed the generation of a high-intensity proton beam of 1,000 nA. • IBA is the world leader in cancer diagnostic systems and the recipient of a contract to install a Cyclone 70 system at the Institute for Basic Science in Daejeon, South Korea. The project will cost between US$ 13 and US$ 16 million, all of which will be financed through IBA. • IONETIX, a leading cyclotron technology, and isotope manufacturing company, acquired a 10,300 sq. ft. facility in Lansing, MI, for its new Targeted Alpha Radionuclide Manufacturing Center. • The manufacturer IBA and the manufacturer IRE signed a contract to install a cyclotron with an energy of 30 MeV. Further, commissioning is scheduled for 2023. A few of the key primary and secondary sources referred to while preparing the report on the medical cyclotron market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), Scientific Institute for Research, and International Atomic Energy Agency (IAEA).
Advanced Cyclotron Systems Frequently Asked Questions (FAQ)
When was Advanced Cyclotron Systems founded?
Advanced Cyclotron Systems was founded in 2003.
Where is Advanced Cyclotron Systems's headquarters?
Advanced Cyclotron Systems's headquarters is located at 7280 River Road, Richmond.
Who are Advanced Cyclotron Systems's competitors?
Competitors of Advanced Cyclotron Systems include Direct Kinetic Solutions and 4 more.
Compare Advanced Cyclotron Systems to Competitors
Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry. The company aims to become a major player in managing high risk pregnancies by commercialising a technology platform of versatile biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies.
Essential Group is a specialty clinical research and patient recruitment service organization.
The company provide clinical research services to area physicians in a range of therapeutic specialties and contract with pharmaceutical companies and contract research organizations (CROs) to conduct in-patient clinical research. The company have successfully conducted more than 500 Phase I, II, III, and IV clinical trials and utilize the Clinasyst Software System for trial management with a database of greater than 40,000 subjects.
Sequenom Center for Molecular Medicine (SCMM) is an molecular pathology laboratory created specifically to support cutting-edge diagnostics, translational research and clinical trials. SCMM is primarily focused on the areas of technology development, women's health and oncology. Based in Grand Rapids, Michigan, SCMM collaborates with Spectrum Health, one of Michigan's largest not-for-profit health systems which annually aims to serve hundreds of thousands of patients, and the Van Andel Research Institute, which aims to offer translational research and bioinformatics expertise with the latest in genomics and proteomics technology.
Velos provides software solutions for clinical research management. It offers a software platform with an automated research review and biospecimen management solution for trial administration, financial management, patient tracking, reporting, and many other purposes. The company was founded in 1996 and is based in Fremont, California.
Quartzy is a free lab management solution for small and medium-sized research and development organizations to manage their inventory, streamline purchasing communications, and consolidate orders. It was founded in 2009 and is based in Hayward California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.